Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology"
DOI: 10.1002/hep.28946
Abstract: zumab, Secukinumab, and Brodalumab) are being evaluated for treatments of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. The current study by Gomes and coworkers adds interesting insights into the cellular and molecular mechanisms underlying… read more here.
Keywords: t39 step; closer treating; lxr inhibiting; inhibiting t39 ... See more keywords